Range Cancer Therapeutics ETF (CNCR)
| Assets | $11.79M |
| Expense Ratio | 0.79% |
| PE Ratio | n/a |
| Shares Out | 830,814 |
| Dividend (ttm) | n/a |
| Dividend Yield | n/a |
| Ex-Dividend Date | n/a |
| Payout Ratio | n/a |
| 1-Year Return | +27.03% |
| Volume | 705 |
| Open | 14.49 |
| Previous Close | 14.38 |
| Day's Range | 14.31 - 14.49 |
| 52-Week Low | 11.27 |
| 52-Week High | 17.96 |
| Beta | 0.83 |
| Holdings | 77 |
| Inception Date | Oct 13, 2015 |
About CNCR
Fund Home PageThe Range Cancer Therapeutics ETF (CNCR) is an exchange-traded fund that is based on the Range Oncology Therapeutics index. The fund tracks an equal-weighted index of companies currently developing oncology drugs or selling cancer therapeutic products. CNCR was launched on Oct 13, 2015 and is issued by Range.
Top 10 Holdings
19.71% of assets| Name | Symbol | Weight |
|---|---|---|
| Recursion Pharmaceuticals, Inc. | RXRX | 2.75% |
| Monte Rosa Therapeutics, Inc. | GLUE | 2.30% |
| ImmunityBio, Inc. | IBRX | 2.07% |
| Replimune Group, Inc. | REPL | 1.91% |
| Ginkgo Bioworks Holdings, Inc. | DNA | 1.88% |
| Revolution Medicines, Inc. | RVMD | 1.87% |
| Exelixis, Inc. | EXEL | 1.86% |
| Xencor, Inc. | XNCR | 1.72% |
| Bristol-Myers Squibb Company | BMY | 1.68% |
| SpringWorks Therapeutics, Inc. | SWTX | 1.67% |
News
Disruptive Theme of the Week – Breakthroughs in Medicine
Medical breakthroughs are occurring constantly, but they often get lost in the news headlines unless they directly impact our lives. I wanted to take a moment to highlight a few recent medical breakth...
EXCHANGE TRADED CONCEPTS, LLC., ANNOUNCES COMPLETION OF FUND REORGANIZATION
OKLAHOMA CITY , Oct. 23, 2023 /PRNewswire/ -- Exchange Traded Concepts, LLC, adviser to the Range Cancer Therapeutics ETF (CNCR) and the Loncar China BioPharma ETF (CHNA) is pleased to announce the co...
Oncology ABCs: A Small-Cap Biopharma Prospectus Series
Oncology remains the fastest growing pharma segment, where innovation is largely driven by emerging small companies. The global oncology market is estimated at c US$175–180bn and is anticipated to mor...
Should Investors Follow Private Equity into Life Sciences?
Reflecting what it considers the vast potential of life sciences companies, Bain Capital is making another huge bet on the industry. The Boston-based investment firm has raised $1.9 billion in a new f...
Biotech Innovations Remain At Forefront
The first quarter of 2021 was challenging for the biotechnology industry, as the selloff in March represented a sharp reversal from record highs in February. While the sector has remained relatively r...
Moving Beyond COVID In Biopharma
Just over one year after COVID-19 disrupted our lives, we are now getting to the point where multiple vaccine options are nearly ubiquitous for those in the United States. Per the CDC, as of April 12,...
Biotech ETFs extend January gains
Biotech exchange-traded funds rallied Monday as investors continued to monitor the sector and its impact on the coronavirus pandemic. The ETFMG Treatments Testing and Advancement ETF gained 4.6% mid-m...
Specialty biotech funds jump on promising coronavirus, funding news
Specialized health-care exchange-traded funds outperformed the broader stock market Wednesday even as stocks rebounded from a sell-off that left the Nasdaq Composite Index in correction territory. Th...
6 Best Biotech ETFs to Buy for Cutting-Edge Growth
Biotech ETFs are, in a word, hot.
3 ETFs For More Moderna Bets
Shares of biotechnology company Moderna Inc (NASDAQ: MRNA) jumped 20% Monday on news that its mRNA-1273 coronavirus vaccine candidate is making positive progress.